Dr. Jorge Garcia on METEOR Trial for RCC

Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the randomized phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC).

In the study, which led to the April 2016 FDA approval of cabozantinib for RCC, more than 600 patients were randomized to receive oral cabozantinb at 60 mg or everolimus at 10 mg daily. The primary endpoint was progression-free survival (PFS) with a secondary endpoint of overall survival (OS), Garcia explains.

Results showed that there was a significant PFS improvement in the patients who received cabozantinib versus everolimus, at 7.4 months and 3.9 months, respectively. The median OS was 21.4 months with cabozantinib and 16.5 months with everolimus. The objective response rate per independent review was 17% in the cabozantinib arm versus 3% in the everolimus arm. Subset analyses show that treatment with cabozantinib improves both PFS and OS, Garcia explains.